Pharmaceutical company Crossject (Euronext Growth Paris:ALCJ) on Wednesday announced progress in the development of ZEPIZURE Junior, its needle-free emergency treatment for paediatric epilepsy.

The company has successfully calibrated its ZENEO autoinjector to deliver the appropriate drug penetration depth for children.

This advancement follows the completion of a clinical echography study involving 90 participants aged 2 to 18, comparing paediatric and adult thigh tissue characteristics. Complementary ex-vivo studies confirmed the suitability of ZENEO's pressure calibration for the paediatric population.

The findings validate the safe and effective use of ZEPIZURE Junior, ensuring proper drug delivery during seizures in children. Prior Human Factors studies also demonstrated that children aged 8 and above can use the device correctly.

Crossject is developing ZEPIZURE under a contract with the Biomedical Advanced Research and Development Authority (BARDA). The company is currently in advanced stages of development and registration for the adult version of the treatment.

According to US Centers for Disease Control and Prevention data, approximately 456,000 children in the United States are living with active epilepsy.